secwatch.observer — SEC 8-K summary
======================================

Issuer:     InfuSystem Holdings, Inc (INFU)
CIK:        0001337013
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001628280-22-028748
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InfuSystem reports record Q3 revenue $27.3M; net income turns positive; FY guidance at low end
--------------------------------------------------------------------------------

- Record Q3 net revenue $27.3M (+3% YoY); ITS segment revenue record $17.4M (+5% YoY).
- Net income $0.4M ($0.02/diluted) vs net loss $0.4M in prior-year quarter; operating income up $1.3M to $0.9M.
- Gross margin improved 200 bps to 59.5%; ITS gross margin 65.6%, DME 48.7%.
- FY2022 guidance: revenue ~$112M (low end of prior 10-13% growth); Adj. EBITDA ~$22M (19-20% margin).
- Nov 3: formed wound therapy partnership with Sanara MedTech and signed distribution agreement with Cork Medical.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1337013/000162828022028748/0001628280-22-028748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1337013/000162828022028748/infu-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-028748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer